CHF6333

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

76 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

1

Cipro

Bayer

Approved

12

Tobrex

VViatris Specialty LLC

Approved

23

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

24

Garamycin

SSchering-Plough

Approved

15

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

16

Foradil

Viatris

Approved

—7

Qvar

SSchering-Plough

Approved

—8

Osmitrol

BB. Braun Medical Inc.

Phase 3

19

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

110

Daliresp

AstraZeneca

Phase 2

4Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bronchiectasis1 trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting·Chiesi Farmaceutici S.p.A.·Phase 1/2·NCT06166056·45 enrolled

Tics1 trial

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects

Completed·Chiesi Farmaceutici S.p.A.·Phase 1·NCT03056326·72 enrolled

Details

Drug Info

Related News